Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;38(2):337-360.
doi: 10.1016/j.hoc.2023.12.002. Epub 2023 Dec 26.

Monoclonal Antibodies in the Treatment of Multiple Myeloma

Niels W C J van de Donk  1 , Sonja Zweegman  2
Affiliations
Review

Monoclonal Antibodies in the Treatment of Multiple Myeloma

Niels W C J van de Donk et al. Hematol Oncol Clin North Am. 2024 Apr.

Abstract

The incorporation of monoclonal antibodies into backbone regimens has substantially improved the clinical outcomes of patients with newly diagnosed and relapsed/refractory multiple myeloma (MM). Although the SLAMF7-targeting antibody elotuzumab has no single- agent activity, there is clinical synergy between elotuzumab and immunomodulatory drugs in patients with relapsed/refractory disease. Daratumumab and isatuximab are CD38-targeting antibodies which have single-agent activity and a favorable safety profile, which make these agents an attractive component of combination regimens. Monoclonal antibodies may cause infusion-related reactions, but with subcutaneous administration these are less frequently observed. All therapeutic antibodies may interfere with assessment of complete response. Next-generation Fc-engineered monoclonal antibodies are in development with the potential to further improve the outcome of patients with MM.

Keywords: BCMA; CD38; Daratumumab; Elotuzumab; Isatuximab; Monoclonal antibody; Myeloma; SLAMF7.

PubMed Disclaimer

Conflict of interest statement

Disclosure N.W.C.J. van.de.Donk has received research support from Janssen Pharmaceuticals, United States, Amgen, United States, Celgene, United States, Novartis, Switzerland, Cellectis and BMS, and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Abbvie, Novartis, Bayer, Adaptive, and Servier, all paid to institution; S. Zweegman. has received research funding from Celgene, Takeda, Janssen, United States, and serves in advisory boards for Janssen, Takeda, BMS, Oncopeptides and Sanofi, all paid to institution; no funding received for this article.

Publication types

MeSH terms

Substances